drugset / Trial / NCT05638620

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

NCT05638620

Phase 1 Completed 20 enrolled Jonathann Kuo, MD
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.

Timeline

Start
2023-01-03
Primary completion
2023-06-15
Completion
2023-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Bupivacaine Other / unclassified 0.5 % Other